DNA damage repair in breast cancer and its therapeutic implications

Reem Ali(Hamad bin Khalifa University), Helen E. Bryant(University of South Alabama), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Emad A. Rakha(Nottingham University Hospitals NHS Trust)
Pathology
December 26, 2016
10.1016/j.pathol.2016.11.002
Cited by 70

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
|The Lancet Oncology|2015|282